GlassScriptPhysician profile
Michael F Giitter
NPI 1851406524
$4,468.53
in general payments reported to CMS, 2019-2025
37 companies · $938 in 2025
The $938 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.63 · 2021: $321 · 2022: $1,119 · 2023: $1,054 · 2024: $1,014 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $710.42 | 2022-2025 | |
| Lilly USA, LLC | $662.31 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $524.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $311.39 | 2022-2025 | Rexulti |
| Amgen INC. | $297.52 | 2020-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.01 | 2021-2025 | Synjardy, Tradjenta, Jardiance |
| Abbvie INC. | $263.37 | 2021-2025 | |
| Astellas Pharma US INC | $148.69 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $134.50 | 2022-2025 | |
| Boston Scientific Corporation | $124.35 | 2021-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $89.88 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $74.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $70.19 | 2022-2024 | Bydureon, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $69.57 | 2022 | |
| Gilead Sciences, INC. | $64.47 | 2022-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giitter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.